

Amendments to the Claims

This listing will replace all prior versions and listings of the claims.

Listing of Claims:

1. (withdrawn) An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;

(f) a polynucleotide which is a variant of SEQ ID NO:X;

(g) a polynucleotide which is an allelic variant of SEQ ID NO:X;

(h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;

(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2-12. (canceled)

13. (withdrawn) An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14-16. (canceled)

17. (withdrawn- currently amended) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim ~~3011~~.

18. (withdrawn) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. (withdrawn- currently amended) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim ~~3011~~ in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. (withdrawn- currently amended) A method for identifying a binding partner to the polypeptide of claim ~~3011~~ comprising:

(a) contacting the polypeptide of claim ~~3011~~ with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21. (canceled)

22. (withdrawn) A method of identifying an activity in a biological assay, wherein the method comprises:

(a) expressing SEQ ID NO:X in a cell;

- (b) isolating the supernatant;
- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. (withdrawn) The product produced by the method of claim 20.

24. (withdrawn) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide of claim 1.

25. (previously presented) An isolated protein comprising amino acid residues 2 to 220 of SEQ ID NO:105.

26. (previously presented) The isolated protein of claim 25 which comprises amino acid residues 1 to 220 of SEQ ID NO:105.

27. (previously presented) The protein of claim 25 which further comprises a polypeptide sequence heterologous to SEQ ID NO:105.

28. (previously presented) A composition comprising the protein of claim 25 and a carrier.

29. (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 25 by a cell; and
- (b) recovering said protein.

30. (previously presented) An isolated protein comprising the amino acid sequence of the complete polypeptide encoded by the HAUAQ39 cDNA contained in ATCC Deposit No. 209145, excepting the N-terminal methionine.

31. (previously presented) The isolated protein of claim 30 which comprises the amino acid sequence of the complete polypeptide encoded by the HAUAQ39 cDNA contained in ATCC Deposit No. 209145.

32. (previously presented) The protein of claim 30 which further comprises a polypeptide sequence heterologous to SEQ ID NO:105.

33. (previously presented) A composition comprising the protein of claim 30 and a carrier.

34. (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 30 by a cell; and
- (b) recovering said protein.